Sparta Trial Logo: Researching Ways to Battle Cancer

The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of SPARTA/APL-101.

The Phase 2 portion will assess the efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.

Who can participate in the SPARTA study?

You may be eligible to participate in the SPARTA study if you meet the following requirements: 

  • Are at least 18 years of age or older. 
  • Have been diagnosed with Non-Small Cell Lung Cancer or another advanced solid tumor with an altered c-Met pathway. 
  • Have not received standard cancer therapy or received standard cancer therapy that is no longer effective or is causing too many side effects. 

Other requirements to participate will apply.

Complete the preliminary pre-screener to see if you qualify. 

Study Details

Age(s): 18 years and older

Condition or Disease: Solid Tumor, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme

Intervention/Treatment: APL-101 Oral Capsules

Phase: Phase 1

Study Type: Interventional

Estimated Enrollment: 201

Primary Purpose: Treatment

Actual Study Start Date: September 27, 2017

Estimated Primary Completion Date: September 30, 2021

Estimated Study Completion Date: December 30, 2022 12:00 am

Interested in this study?
Take the pre-screener to see if you qualify
See if you qualify

General Information

Apollomics Inc.

Trial Name:
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Trial Number:
APL-101-01 (CBT-101-01) Identifier:

Recruitment Status:

First Posted:
June 5, 2017

Last Update Posted:
October 30, 2020